SeqCenter Acquired by ARCHIMED in Strategic NGS Expansion
Deal News | Nov 10, 2024 | Archimed SAS
Global private equity healthcare specialist ARCHIMED has acquired SeqCenter, a Pittsburgh-based genetic sequencing provider, marking a significant step in the Next-Generation Sequencing (NGS) sector. SeqCenter, founded by scientists from the University of Pittsburgh in 2019, leverages cutting-edge NGS technologies which allow rapid, reliable, and cost-effective gene sequencing. The acquisition is part of ARCHIMED's strategy to enhance its Diagnostics and Life Science sector offerings, aiming to drive SeqCenter's growth across Europe and Asia. SeqCenter's diverse client base spans academic institutions, biotech firms, agricultural sectors, and governmental agencies, which utilize its services for advancing health-related research and applications. The acquisition was facilitated through ARCHIMED's MED Rise fund, which targets buyouts valued at 10 million to 30 million and closed at 400 million last April. The acquisition underscores ARCHIMED’s commitment to investing in transformative life science technologies, aligning with its MedDiscover initiative. SeqCenter is expected to benefit significantly from ARCHIMED's international capabilities and sector expertise.
Sectors
- Healthcare
- Biotechnology
- Private Equity
Geography
- United States – The United States is the location of SeqCenter's base of operations in Pittsburgh, Pennsylvania, making it a relevant geography for the acquisition.
- Europe – ARCHIMED aims to internationalize SeqCenter's operations in Europe, marking it as a strategic geography for future expansion.
- Asia – Asia is another target geography for SeqCenter's expansion, leveraging ARCHIMED's global network.
Industry
- Healthcare – The healthcare industry relates to companies that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or facilitate the provision of healthcare to patients. SeqCenter's operations in gene sequencing are a crucial part of the modern healthcare landscape.
- Biotechnology – Biotechnology involves the use of living systems and organisms to develop or make products, often focusing on genetic engineering and sequencing. SeqCenter's role in gene sequencing technology positions it firmly within this sector.
- Private Equity – Private equity pertains to capital investment made into companies that are not publicly traded. ARCHIMED, as a healthcare-focused private equity firm, is a key player in this sector.
Financials
- 400 million – The hard cap size of ARCHIMED's MED Rise fund, used to acquire SeqCenter, indicating the financial capacity and intent of the acquiring party.
- 10 million to 30 million – The typical target valuation range for buyouts by ARCHIMED's MED Rise fund.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SeqCenter | Target | Company | A leader in Next-Generation Sequencing, providing rapid and cost-effective gene sequencing services. |
| ARCHIMED | Bidding Company | Company | A global private equity firm specializing in healthcare investments, known for its strategic sector play in life sciences. |
| University of Pittsburgh | Other | Organization | The founding scientists of SeqCenter initially worked here, highlighting its role in SeqCenter's origins. |
| Dan Snyder | CEO and Founder | Person | Founder and CEO of SeqCenter, retaining equity through a significant rollover of sale proceeds. |